Development and initial validation of a fertility experiences questionnaire by unknown
Thomas et al. Reproductive Health  (2015) 12:62 
DOI 10.1186/s12978-015-0054-3RESEARCH Open AccessDevelopment and initial validation of a
fertility experiences questionnaire
F. Scarlett Thomas1, Joseph B. Stanford1,3*, Jessica N. Sanders1,3, Shawn E. Gurtcheff2, Mark Gibson3,
Christina A. Porucznik1 and Sara E. Simonsen1Abstract
Background: Many women throughout the world have history of subfertility (resolved or unresolved), but much
remains unknown about services and treatments chosen.
Methods: We developed a mixed-mode fertility experiences questionnaire (FEQ) in 2009 through literature review
and iterative pilot work to optimize question format and mode of administration. The focus of the FEQ is to collect
data retrospectively on time at risk for pregnancy, fertility treatments received and declined, pregnancy, time to
pregnancy and pregnancy outcomes. We conducted a validation of key elements of the FEQ with comparison to
medical records in 2009 and 2010. The validation sample was selected from women initially seen at a specialized
fertility treatment center in Utah in 2004.
Results: The FEQ was optimized with two components: 1) written (paper or web-based), self-administered, followed
by 2) telephone- administered questions. In 63 patients analyzed, high levels of correlation were identified between
patient self-report and medical records for the use of intrauterine insemination and assisted reproductive technology,
pregnancy and live birth histories, time at risk for pregnancy and time to pregnancy. There was low correlation between
medical records and self-report for the use of oral ovulation drugs and injectable ovulation drugs. Compared to the
medical record, the FEQ was over 90 % sensitive for all elements, except injectable ovulation drugs (70 % sensitivity).
Conclusions: The FEQ accurately captured elements of fertility treatment history at 5–6 years after the first visit to a
specialty clinic.
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Subfertility (also called infertility) is a prevalent condition
throughout the world [1, 2]. Based on the conventional
definition of no pregnancy within a year of intercourse
without contraception, the prevalence of subfertility is es-
timated at 15 % or more among couples currently trying
to conceive in developed countries [2–4]. Many women or
couples experiencing subfertility never seek services, and
among those who do, the level of services received varies
widely [5–7]. In addition to accessibility of medical ser-
vices, demographic and social factors are strongly* Correspondence: joseph.stanford@utah.edu
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creativecommons.org/publicdomain/zero/1.0/correlated with the types and volume of fertility treat-
ments received [8, 9].
Questionnaires can provide valuable information on
many aspects of subfertility, including its epidemiology,
psychological aspects, and women’s and couple’s deci-
sions about treatment. Such information is essential to
inform efforts to improve medical treatment and to
guide policy regarding the allocation of resources to di-
minish the societal and economic burden of subfertility
[7, 10]. However, questionnaire research to date in the
field has been largely ad hoc, and many questionnaires
have not been validated.
Our goal was to generate a questionnaire instrument
that can be used retrospectively to ascertain fertility
treatments chosen by women, reasons for choosing or
declining different treatments, factors that may have in-
fluenced choices of treatments, timing of treatments,article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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we mean time at risk for pregnancy, as defined further
below). We conducted a validation comparing important
components of the questionnaire with data from medical
records in a clinical sample.Methods
Design of the questionnaire
We initially conducted a literature review to identify ques-
tionnaires that possibly included domains of interest for
our research [7, 11–20]. We also contacted authors to ob-
tain copies of their instruments, where possible. We used
items verbatim from some questionnaires [12, 13], and
adapted items from others (as referenced in Table 1).
Based on this review and consultation with experts in the
field, we constructed a questionnaire with the domains of
interest for our research, called here the fertility experi-
ences questionnaire (FEQ).Pregnancies and time at risk for pregnancy
We were particularly interested in assessing time at risk
for pregnancy, pregnancies, and pregnancy outcomes
retrospectively. The “pregnancies and attempts to con-
ceive” component of the FEQ captures information
about all time in a woman’s life when she was at risk of
pregnancy, whether or not she was “trying” to conceive,
and whether or not the “attempt” ended in pregnancy.
Each time at risk for pregnancy is called an “attempt” to
conceive in the FEQ. This written questionnaire contains
a definition as well as an illustrative example for “at-
tempts to conceive” to enhance respondents’ under-
standing of the concept of “attempts to conceive.” (See
Additional file 1 for the full FEQ, which includes the
exact definition and examples used in the online portion
of the “Attempts to Conceive” section.) Several initial
questions are asked in the written questionnaire, with a
follow-up telephone interview for further verification
and clarification. The goal is to capture as accurately as
possible the time a woman was actually at risk of preg-
nancy. Unlike other time to pregnancy questions that
ask a woman to give a general number of months it took
her to become pregnant, the “attempts to conceive” sec-
tion specifically excludes time that a woman was not at
risk for pregnancy (for example, due to spousal separation,
or desire not to have a baby in a certain month), even
though she may have intended to achieve a pregnancy
[21]. It also explicitly includes time that a woman was at
risk of pregnancy without intending pregnancy [22]. Dates
(month and year) are established for specific definitions of
beginning an “attempt to conceive” and when the preg-
nancy occurred, similar to an approach previously used by
European investigators in an interview questionnaire, but
with some additional details [23]. For “attempts” thatended in pregnancy, there were additional questions about
the outcome of the pregnancy.
Other components of the FEQ
Other components of the FEQ addressed fertility evalu-
ation and treatment, women’s general health, menstrual
and sexual history, and psychological and social factors.
All components of the FEQ are outlined in Table 1. The
complete FEQ is in the Additional file 1.
Pilot testing
We pilot tested the FEQ in four sequential phases: entirely
by self-administration (written on paper, 10 women), en-
tirely by face-to-face interview (5 women), entirely by tele-
phone interview (3 women), and by mixed-mode of
administration (written online, followed by interview, 30
women). All participants in the pilot testing were current
patients of a specialty fertility clinic, the Utah Center for
Reproductive Medicine (UCRM). The 18 women partici-
pating in the first three phases were a convenience sample
from women being seen in the clinic during the time of
the development work. The 30 women in the fourth phase
were a random sample and were also included as the first
group of women in the validation analysis, described in
the next section below.
After each administration of the FEQ, a semi-structured
debriefing interview was conducted (in person or by tele-
phone) that explored which questions were perceived as
difficult, confusing, or objectionable. Revisions of wording
of some items and responses were undertaken after the
first three phases. We also reviewed the time required to
complete the FEQ and the consistency of responses in
these phases. Oral interviews obtained information on
time to conceive (as described above) that was more in-
ternally consistent than complete self-administration on
paper. We also found that we had more complete and in-
ternally consistent information regarding pregnancy out-
comes, fertility treatments, and self-help measures when
these were assessed first in writing, with a follow-up tele-
phone interview. Finally, we found that mixed-mode ad-
ministration was more efficient than complete oral
interviews and yielded internally consistent information
on parts of the questionnaire that were not temporally tied
to attempts to conceive.
Validation
This validation includes two groups of women. (See
Fig. 1) The original group was selected via random sam-
ple of women over the age of 18 who had an initial con-
sultation for subfertility generally, or in vitro fertilization
(IVF) specifically at the UCRM in the year 2004. There
were no other exclusion or inclusion criteria for this
group. In 2009, we attempted to contact each woman by
telephone three times at different times on a day,






General health [28] X Exercise, tobacco, caffeinated beverages, alcohol, past medical history, pap smear
Menstrual history X Age at menarche, frequency and intensity of menses (when not taking hormonal
birth control or fertility treatment)







Start month/year for “attempt,” how attempt started and ended, partner for attempt
Desire to conceive during each
attempt [29]
X Likert scale for desire for pregnancy and pereceived partner desire for pregnancy at
beginning, middle and end of each attempt
Pregnancy outcomes [11] Dates and types
of outcomes
Verification and details Live birth, miscarriage, ectopic, stillbirth, molar pregnancy, termination, currently
pregnant, other, and date ended. For live birth: state where born, birth weight, sex,
hospital stay of 7 days or more, breastfeeding.
Fertility-related medical evaluationsb X Ultrasound of uterus/ovaries, follicular ultrasound, hysterosalpingogram, hysteroscopy,
D&C, blood tests
Fertility-related surgeriesb X C-section, cervical cryotherapy or LEEP, laparoscopy, laparotomy, surgical treatment of
endometriosis, surgery on ovaries, tubes, or uterus, other abdominal or pelvic surgery,
partner vasectomy reversal, partner other urologic surgery
Fertility-related diagnosesb X Unexplained infertility, endometriosis, PCOS, low progesterone or estrogen,
not ovulating, abnormal ovulation, limited cervical mucus, pelvic adhesions,
blocked fallopian tubes, uterine fibroids, uterine polyps, luteal phase defect,
male factor, other
Fertility treatments recommended
by physician or practitioner, and
reasons for using or declining
treatments
X Details about treatments received,
and linking timing to attempts to
conceive, and whether linked to
conception
Fertility-enhancing drugs, artificial insemination, in vitro fertilization with or without
intracytoplasmic sperm injection, donor semen or donor eggs, acupuncture, fertility
diets, herbal treatments
Self-help measures for trying to
conceive (fertility awareness, diet, etc.)
Ascertained and linked to attempts to
conceive, and whether linked to
conception
Timed intercourse by counting days, basal body temperature, urine ovulation test kits,
cervical mucus or fluid; took herbs, fertility vitamins, or supplements; lost weight;
adhered to fertility diets; took a daily drug to enhance fertility; took a drug for ovulation;
took hormones like progesterone
Adoption experiences X Ever applied for adoption, any adopted children
Stress and social situation [12] X Likert scale questions about impact of fertility problems and/or treatment on life,
relationships with partner, family, friends; level of support from family, partner, friends;
negative reactions from family, partner, friends.
Experience of past fertility
treatment[12]
X Likert scale questions about perceptions of past treatment: had enough time,
shared decision making, feeling listened to, receiving explanations, addressing
emotional issues
Demographic information X Marital status and date, education, race, ethnicity, country of birth, country of parents’
birth, languages spoken, religious preference, occupation, income, whether have written












Table 1 Domains, components, details and sources in the fertility experiences questionnaire (Continued)
Friends and family with infertility X Number of friends or family diagnosed with infertility, friends or family members who
have used any of the fertility measures listed previously above
Hypothetical interest in participating
in studies of fertility treatment
X Would she have been willing to participate in a study that would involve lifestyle advice,
education about fertile days, herbs or acupuncture, medication, artificial insemination, or IVF.
Sources of information X X Did the participant consult written records to complete the questionnaire?
aCitations indicate other studies from which sections of the questionnaire were taken or adapted












Fig. 1 Recruitment and enrollment
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receive information about the study. If she agreed, we
obtained an e-mail address where we sent an e-mail de-
scribing this study. Included in the email was an attach-
ment of a consent document as well as a link to the
questionnaire and instructions to decline participation if
she chose to do so. Women consented by clicking on
the link to begin answering the questionnaire. Women
who completed the online questionnaire were contacted
by telephone for the follow-up interview at a time of
their convenience to conduct the telephone component
of the FEQ, the follow up interview typically occurred
within 2 weeks of completion of the written survey.
There was no compensation for these women.
A subsequent or expanded group was selected from
the remainder of the UCRM patients who were also
first seen for infertility or IVF in 2004; this group par-
ticipated in a follow-on study that had additional eligi-
bility criteria. These women all received a mailing in
2010 inviting them to contact the study investigators if
they were interested in participation. Those who did so
were screened for eligibility based on primary subferti-
lity (defined by being at risk for pregnancy for
12 months with the same partner without pregnancy
and never having a positive pregnancy test prior to be-
ing seen at the clinic) as well as living in Utah at the
time of their appointment. These women received a
$10 gift card for their participation.For all participants, medical records were obtained
from the UCRM for independent chart review to extract
key variables for comparison. Review of medical records
was done by two physicians at the UCRM (S.G., M.G.),
and three medical students under their supervision. Re-
cords from any other clinics that patients may have vis-
ited in addition to UCRM were not available to us for
analysis.
We used data from billing records to compare partici-
pants from both groups described above to all patients
seen at the UCRM during 2004 (the source population,
n = 923) on the characteristics of age, type of visit, and
whether they had a subsequent visit for an early preg-
nancy ultrasound.
For the initial validation, we chose the following vari-
ables to compare between the medical chart review and
the FEQ: use of oral ovulation enhancing drugs, use of
injectable ovulation drugs, use of intrauterine insemin-
ation, use of in-vitro fertilization, time at risk for preg-
nancy, time to pregnancy, pregnancy, and live birth.
These represent the outcomes of greatest interest for
this questionnaire.
Statistical analysis
We performed correlation analyses to determine the de-
gree of agreement between the specified elements in the
questionnaire and the patients’ medical records. For cat-
egorical variables (history of different types of treatment
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specificity, and used Cohen’s kappa statistic to rate inter-
observer agreement [24]. As a sensitivity analysis, we
also repeated these analyses for the women who never
conceived.
From the FEQ interview, we calculated time at risk for
pregnancy starting at the woman’s report of the begin-
ning of the first attempt to conceive. The end point for
the time period was her first clinic visit to UCRM, which
is also the time point that we extracted the time
attempting to conceive that was recorded in the medical
record. Between the start and end points, any time that
was reported as not being at risk for pregnancy in the
FEQ was subtracted from the interview-based time at
risk for pregnancy, but not from the medical record-
based time at risk for pregnancy. For women who had a
pregnancy, we also calculated time to pregnancy. For
this calculation, the same starting point was used from
the FEQ interview, and the end point was the time of
pregnancy, as reported by the woman. For the medical
record, the time attempting to conceive that was re-
corded at the first visit was added to the subsequent
time until the beginning of the first subsequent preg-
nancy identified in the medical record. To compare time
at risk for pregnancy and time to pregnancy between the
FEQ interview and the medical record, we used the
Pearson’s linear correlation coefficient.
Results
Enrollment and sample characteristics
For the initial sample, we attempted to contact 160
women, randomly sampled from UCRM patients that
were first seen in 2004 see (Fig. 1). Eighty-two (54 %)
were not locatable. Of the 69 women (46 %) that we
located, 61 (88 %) agreed to consider participating. Of
these, 34 (56 %) completed the written questionnaire,
and of these, 30 (88 %) completed the follow-up inter-
view. Finally, we were able to locate medical records for
26 (87 %) of the women that completed the follow-up
interview.
In the expanded sample, there were 763 additional
UCRM patients first seen in 2004, of whom 175
responded that they were interested in participating.
Ninety-two (53 %) of these women screened eligible. Of
these women, 64 (68 %) completed both components of
the FEQ. Of these, we were able to locate 41 (64 %)
medical records for review. Subsequently, we determined
that four of these women were seen at UCRM prior to
2004 and we removed them from the final analysis.
Thus, the total sample included in the validation analysis
is 63 women: 26 from the initial sample, plus 37 from
the expanded sample.
The characteristics of the women enrolled are shown
in Table 2, with comparison to all patients seen for firstfertility visits at the UCRM in 2004 (where available
from billing data). In general, participants were highly
educated and with medium to high household income.
About 30 % had never had a pregnancy. Participants
were slightly younger than clinic patients, with a mean
age of 30.4 years, compared to the clinic population
mean of 31.8 years (p = 0.066). Participants were prob-
ably more likely to have had a successful pregnancy, as
65.0 % of participants had a subsequent visit to evaluate
an early pregnancy by ultrasound, whereas 49.0 % of all
clinic patients had such an evaluation (p = 0.014).
Treatment history
The agreement between the FEQ and the medical record
for different treatments is shown in Table 3. Compared
to the medical record, the sensitivity of the FEQ was
uniformly higher than specificity. The agreement was
good for intrauterine insemination and assisted repro-
ductive technology (kappa 0.64, 95%CI 0.46-0.83; and
0.74, 95%CI 0.57-0.90, respectively), but lower for use of
oral ovulation drugs and injectable ovulation drugs
(0.41, 95%CI 0.21-0.61 and 0.21,95%CI 0.0.-0.51, respect-
ively). For women who never conceived (n = 29), the re-
spective kappas were very similar: 0.65 for intrauterine
insemination, 0.68 for assisted reproductive technology ,
0.45 for oral ovulation drugs, and 0.22 for injective ovu-
lation drugs, respectively.
Pregnancy history
The kappa for the agreement for pregnancy history dur-
ing the time the woman was a patient at UCRM was
0.65. There was perfect concordance for 50 (79.4 %) par-
ticipants with respect to the number of pregnancies re-
ported in the interview with the number of pregnancies
reported in the medical record. Nine women (14.3 %) re-
ported more pregnancies in the interview than were re-
ported in the medical record, while one (1.6 %) reported
one fewer pregnancy in the interview than was reported
in the medical record. The kappa for the agreement for
live births a woman had during the time she was a pa-
tient at UCRM was 0.55. 43 (68.3 %) showed perfect
concordance, while 12 (19 %) reported more live births
in the interview than in the medical record and one
(1.6 %) women reported one fewer live birth in the inter-
view than in the medical record.
Time at risk for pregnancy and to time to pregnancy
About half of the medical records did not contain suffi-
ciently detailed information on time attempting to con-
ceive at the first visit. We were able to compare and
calculate time at risk for pregnancy for 35 women, and
time to pregnancy for 29 of those women. The mean
and median time at risk for pregnancy, as reported in
the interviews was 42.1 months and 40 months
Table 2 Characteristics of the women included in the validation study and of their source population
Women in validation study (n = 63) All other patientsa (N = 860) P value**
Mean (S.D.) Mean (S.D.)
Years of age 30.4 (4.7) 31.8 (5.8) 0.066
Visit type N (%) N (%)
Initial infertility visit 48 (76.2) 739 (85.9) 0.035
Initial IVF visit 15 (23.8) 121 (14.1)
Had early pregnancy ultrasound at UCRM 41 (65.0) 422 (49.0) 0.014
Race
White 45 (67.2) NA
Other 8 (11.9)
Household income (in US dollars)
12,000 - 25,000 2 (3.0) NA
25,001 - 50,000 10 (14.9)
50,001 - 75,000 14 (20.9)
75,001 - 100,000 25 (39.7)
Over 100,000 11 (16.4)
Education
Graduated high school 3 (4.8) NA
Some college/vocational school 11 (17.6)
Graduated college 28 (44.4)
Attended graduate school 21 (33.3)
Outcome of fertility treatment
no pregnancy 20 (29.9) NA
pregnancy, no live birth 4 (6.0)
live birth 42 (62.7)
Percentages for some variables do not add to 100 % because of missing data
NA not available
**Comparing women in validation study to all other female patients seen for infertility at the Utah Center for Reproductive Medicine, with the first visit in 2004
aAll other new female patients seen for infertility at the Utah Center for Reproductive Medicine, with the first visit in 2004
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spectively, with a Pearson’s correlation coefficient of 0.42
(95 % CI: 0.10-0.66) (Table 4). For time to pregnancy,
the Pearson’s correlation coefficient was 0.77 (95 % CI:
0.55-0.88) (Table 4 and Fig. 2).
Discussion
We designed the FEQ to cover time at risk of pregnancy,
fertility treatments received, pregnancy outcomes from
those treatments, and a wide range of factors that may
influence choices about fertility treatments. In this initial
validation study, we found that women’s responses to
the FEQ were reasonably comparable to medical records
for total time at risk for pregnancy, time to pregnancy,
pregnancy, live birth, and the use of IVF and artificial in-
semination. However, there was poor correlation be-
tween the FEQ and medical records for the use of oral
or injectable ovulation drugs. Uniformly, sensitivity was
higher than specificity, meaning that women reported
many treatments or events that were not found in themedical record. We believe it is likely that some women
may have obtained treatments from physicians outside
of the UCRM (since we did not have medical record in-
formation from other clinics and in the FEQ did not ask
women at which clinic they had received each treat-
ment). Alternatively, it is possible that women misunder-
stood the questions, or that the use of some treatments
was not completely recorded in the medical record.
Underreporting in the medical record of treatments ac-
tually given at the UCRM is possible for drugs, but we
believe it is much less likely for procedures such as arti-
ficial insemination or IVF.
Although there was substantial agreement in regards
to pregnancies a woman achieved while as a patient in
the clinic, 9 (14 %) of the women interviewed reported
having more pregnancies at the time they were patients
at UCRM than those recorded in their medical record.
This is consistent with the fact that after receiving fertil-
ity treatment at the UCRM, some women go to their
own obstetricians, family physicians, or midwives to
Table 3 Agreement between medical record review and FEQ interview for fertility treatments, and sensitivity and specificity of the
FEQ interview, considering the medical record as the gold standarda
Cohen’s
Ovulation drugs, oral Kappa [95 % CI] Sensitivity [95 % CI] Specificity [95 % CI]
Interview
Yes No 0.41 [0.23-0.93] 91 % [80, 100] 55 % [39, 71]




Yes No 0.26 [0.03-0.51] 70 % [54, 85] 57 % [39, 75]




Yes No 0.64 [0.46-0.83] 93 % [83, 100] 69 % [59, 88]




Yes No 0.74 [0.57-0.90] 96 % [88, 100] 82 % [69, 94]




Yes No 0.65 [0.47-0.84] 97 % [91, 100] 67 % [49, 84]




Yes No 0.55 [0.36-0.75] 96 % [87, 100] 64 % [47, 80]
Medical record Yes 22 1
No 12 21
aSome items were missing in the medical record for some patients, so actual number for each item is less than 63
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prenatal care is not provided at the UCRM). Unless
there is some subsequent contact between the women
and the UCRM, these pregnancies are not documented
in the UCRM records. During this time period, thereTable 4 Correlation between FEQ interview and medical record review
Source Mean Months (S
Time at risk for pregnancy, n = 35 Interview 42.1 (22.5)
Medical record 36.4 (21.7)
Time to pregnancy, n = 29 Interview 40.5 (20.8)
Medical record 36.4 (22.3)
aPearson’s Rhowas routine follow-up from UCRM to women or couples
undergoing IVF, but not necessarily for women undergo-
ing other types of fertility treatment. Probably for the
same reasons, many women who had live births reported
more live births in their interviews than the numberfor duration of time at risk for pregnancy and time to pregnancy
D) Median Months Range, Months Correlationa [95 % CI]
40 7–117 0.42 [0.10-0.66]
30 5 –96
38 14–117 0.77 [0.55-0.88]
29 5–96
Fig. 2 Scatter Plot of time to pregnancy as reported in medical record compared to self-report from interview
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ation studies that allow linkage to medical records of all
providers seen, or perhaps complete visit and pharmacy
billing records, are needed to corroborate our hypothesis
that women reported additional fertility treatment and care
for pregnancy outside of the single specialty clinic studied.
We believe that the most unique and innovative aspect
of the FEQ is that it captures a more accurate and
complete time at risk for pregnancy (called “attempts to
conceive” in the FEQ) than the single measure of time
“trying to conceive” reported in the woman’s medical
record, as evidenced by the 35 (52 %) women in our
sample that reported multiple attempts in the time lead-
ing up to the first clinic visit (for which the clinic visit
identified only one “time trying” to conceive). A woman
might report a longer duration of trying to conceive dur-
ing her first clinic visit than exists in reality, either be-
cause she is anxious to start treatment or because she
did not take into account any gaps between her attempts
to conceive (such as miscarriages, times of separation, or
temporary use of birth control). On the other hand, a
woman may also report a shorter duration than her ac-
tual time attempting to conceive. This may occur when
a woman started having sexual intercourse without
contraception thereby putting herself at risk of preg-
nancy but did not consider herself to be “trying” to
achieve pregnancy until a later point of time. For these
reasons, we have reported the correlation between the
FEQ interview and the medical record for time at risk
for pregnancy, but did not consider the medical record
as a “gold standard” for this information.
In the development and pilot testing of the FEQ, we
found that a combination of written or online questions,followed by a clarifying telephone interview seemed to as-
sure adequate understanding of the concept of “attempt to
conceive.” We found that the written description of “at-
tempt to conceive” (as found in the full FEQ shown in
the Additional file 1) was often not sufficiently under-
stood in the written questionnaire alone. This was the
key issue that led us to develop the FEQ in a mixed
mode, two-step format, with the interview component
focused on clarifying and expanding the information
specifically tied to each attempt to conceive. While this
makes the FEQ more resource-intensive to administer
than an online-only (or written-only) questionnaire, we
anticipate that for some research aims and settings, it
may be worthwhile to collect this detailed information
on time at risk for pregnancy. Other investigators have
also used interviews to assess information about time
at risk of pregnancy across different pregnancies and at-
tempts [23]. While time at risk for pregnancy assessed
retrospectively may be subject to recall bias, others have
shown that the reliability of time to pregnancy recall is en-
hanced when women are queried in-person or via tele-
phone or e-mail [21, 25, 26]. We believe this supports the
value of the two-stage approach to assessing time at risk
for pregnancy we have employed in the FEQ. However, for
other research aims and settings, the written (online or
paper) questionnaire alone may suffice. We plan future re-
search to assess the two-stage, mixed mode assessment in
a prospective cohort.
The FEQ also contains many additional elements not
validated in this study, although many of them have
been used, and some validated, in other studies (see
Table 1). Not all of these elements may be pertinent for
other research uses where the FEQ may be useful.
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pletely reflective of all patients seen at the UCRM in
2004. Among the original sample, 30 of 69 (43 %)
women contacted ultimately completed both compo-
nents of FEQ; while in the expanded sample 68 % of
those eligible completed both components. The differ-
ence in response rate may be related to the $10 compen-
sation provided to the latter group. Those that
participated in this validation study were probably more
likely to have conceived while under care at UCRM, as
we infer from the higher proportion of participants who
received visits for early ultrasound assessment of preg-
nancy (Table 2). Women who had experienced success
were likely more motivated to participate in the study.
We cannot exclude the possibility that recall of events
may be less complete for women who did not conceive
with treatment. There was limited socioeconomic and
ethnic diversity in the clinic population and the study
sample. It would be useful to focus further validation
studies on women from broader cultural and socioeco-
nomic backgrounds, and to include women who did not
conceive with treatment.
Conclusions
This study provides initial validation for key elements el-
ements of a mixed mode questionnaire that can be used
to improve our understanding of the epidemiology of
subfertility in both clinical and population settings, with
focus on the natural history of time at risk at pregnancy,
and its relationship to fertility treatments and pregnancy
outcomes. Our results show high sensitivity for medical
treatments, pregnancies, and live births. As suggested by
other investigators, we have parsed the time aspect for
each attempt to conceive, any fertility treatments re-
ceived, and any pregnancy each woman may have had in
the construction of the questionnaire so that misclassifi-
cation and bias is minimized to the extent feasible in a
retrospective questionnaire [27]. We encourage add-
itional validation from prospective studies. Such infor-
mation can help inform efforts to better to serve the
needs of subfertile couples in the clinical and public
health setting.
Additional file
Additional file 1: Fertility experiences woman’s questionnaire.
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